G. O. Ozgon Et Al. , "VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients," EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.64, no.9, pp.889-894, 2008
Ozgon, G. O. Et Al. 2008. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.64, no.9 , 889-894.
Ozgon, G. O., Langaee, T. Y., feng, h., Buyru, N., Ulutin, T., Hatemi, A. C., ... Siva, A.(2008). VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.64, no.9, 889-894.
Ozgon, G. Et Al. "VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients," EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.64, no.9, 889-894, 2008
Ozgon, G. O. Et Al. "VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients." EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.64, no.9, pp.889-894, 2008
Ozgon, G. O. Et Al. (2008) . "VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients." EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.64, no.9, pp.889-894.
@article{article, author={G. Oner Ozgon Et Al. }, title={VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients}, journal={EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY}, year=2008, pages={889-894} }